Shenzhen New Industries Adjusts Valuation Amidst Flat Financial Performance and Market Trends

Shenzhen New Industries Biomedical Engineering Co., Ltd., a prominent player in the Pharmaceuticals & Biotechnology sector, has recently experienced an adjustment in its evaluation. The company’s valuation score has been revised, reflecting a shift in its financial metrics and market position. Currently, the stock exhibits a P/E ratio of 21, indicating its earnings relative to its share price. The Price to Book Value stands at 3.51, while the EV to EBIT and EV to EBITDA ratios are recorded at 17.04 and 15.54, respectively. The EV to Capital Employed ratio is noted at 4.37, and the EV to Sales ratio is 6.74. Additionally, the company offers a dividend yield of 2.83%, which may attract income-focused investors. Despite these metrics, the company has shown a flat financial performance in the recent quarter ending June 2026. Over the past five years, net sales have grown at an annual rate of 13.46%, with operating profit increasing at 20.57%. However, the stock has generated a return of -19.64% over the past year, alongside a decline in profits by -11.3%. This evaluation adjustment reflects the ongoing trends within the company and its market environment. Discover the Latest Mojo Score and Financial Trend Performance - SignUp in less than 2 Minutes and get FREE Premium Access.